litlas
Log inCreate account

Jonathan Strosberg

Active 2006–2025

112
Papers
18,798
Citations
69
h-index
110
i10-index

Citations

Citations per year for Jonathan Strosberg1984: 2 citations2004: 1 citations2007: 3 citations2008: 3 citations2009: 3 citations2010: 14 citations2011: 41 citations2012: 53 citations2013: 54 citations2014: 67 citations2015: 73 citations2016: 91 citations2017: 166 citations2018: 206 citations2019: 721 citations2020: 873 citations2021: 878 citations2022: 647 citations2023: 488 citations2024: 868 citations2025: 321 citations1985–2003: no citations, so these years are not shown2005–2006: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,208 citing papers, 22.7% of this breakdownItaly: 449 citing papers, 8.4% of this breakdownChina: 411 citing papers, 7.7% of this breakdownGermany: 393 citing papers, 7.4% of this breakdownUnited Kingdom: 302 citing papers, 5.7% of this breakdownFrance: 290 citing papers, 5.4% of this breakdownNetherlands: 253 citing papers, 4.7% of this breakdownSwitzerland: 180 citing papers, 3.4% of this breakdownCanada: 175 citing papers, 3.3% of this breakdownSpain: 155 citing papers, 2.9% of this breakdownSweden: 148 citing papers, 2.8% of this breakdownAustralia: 131 citing papers, 2.5% of this breakdown
0%22.7%Other 23.1%

Institutions

Fields

  • Medicine89.3%
  • Biochemistry, Genetics and Molecular Biology8%
  • Immunology and Microbiology0.5%
  • Engineering0.5%
  • Materials Science0.3%
  • Neuroscience0.3%
  • Other1.1%

Topics

  • Neuroendocrine Tumor Research Advances21.5%
  • Lung Cancer Research Studies14.5%
  • Neuroblastoma Research and Treatments8.7%
  • Radiopharmaceutical Chemistry and Applications5.7%
  • Pancreatic and Hepatic Oncology Research4.9%
  • Thyroid Cancer Diagnosis and Treatment2.5%
  • Other42.2%

Coauthors

All papers

Open in search
  1. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

    Authors: Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning - New England Journal of Medicine 2017 cited by 3,178

  2. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    Authors: James C. Yao, Nicola Fazio, Simron Singh, Roberto Buzzoni, Carlo Carnaghi, Edward M. Wolin, Jiří Tomášek, Markus Raderer, Harald Lahner, Maurizio Voi, Lida Pacaud, Nicolas Rouyrre, Carolin Sachs, Juan W. Valle, Gianfranco Delle Fave, Eric Van Cutsem, Margot Tesselaar, Yasuhiro Shimada, Do‐Youn Oh, Jonathan Strosberg, Matthew H. Kulke, Marianne Pavel - The Lancet 2015 cited by 1,264

  3. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    Authors: Manisha H. Shah, Whitney Goldner, Al B. Benson, Emily K. Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, J.K.C. Chan, Satya Das, Paxton V. Dickson, Paul T. Fanta, Thomas J. Giordano, Þorvarður R. Hálfdánarson, Daniel M. Halperin, Jin He, Anthony P. Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid Khan, Boris W. Kuvshinoff, Christopher H. Lieu, Kimberly D. Miller, Venu G. Pillarisetty, Diane Reidy‐Lagunes, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan Strosberg, Craig Sussman, Nikolaos A. Trikalinos, N. Uboha, Namrata Vijayvergia, Terence Z. Wong, Beth Lynn, Cindy Hochstetler - Journal of the National Comprehensive Cancer Network 2021 cited by 602

  4. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

    Authors: Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, Edmond L. Schmulbach, Diane Reidy‐Lagunes, Jonathan Strosberg, Peter J. O’Dwyer, Al B. Benson - Journal of Clinical Oncology 2022 cited by 294

  5. Gastroenteropancreatic Neuroendocrine Tumors

    Authors: Mauro Cives, Jonathan Strosberg - CA A Cancer Journal for Clinicians 2018 cited by 608

  6. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

    Authors: Jonathan Strosberg, Edward M. Wolin, Beth Chasen, Matthew H. Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela L. Kunz, Timothy J. Hobday, Andrew Hendifar, Kjell Öberg, Maribel Lopera Sierra, Thomas Thevenet, Inés Margalet, Philippe Ruszniewski, Eric P. Krenning, on behalf of the NETTER-1 Study Group - Journal of Clinical Oncology 2018 cited by 389

  7. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

    Authors: Satya Das, Taymeyah Al‐Toubah, Ghassan El‐Haddad, Jonathan Strosberg - Expert Review of Gastroenterology & Hepatology 2019 cited by 126

  8. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

    Authors: Valentina Ambrosini, Jolanta Kunikowska, Eric Baudin, Lisa Bodei, Catherine Bouvier, Jaume Capdevila, Marta Cremonesi, Wouter W. de Herder, Clarisse Dromain, Massimo Falconi, Melpomeni Fani, Stefano Fanti, Rodney J. Hicks, Levent Kabasakal, Gregory Kaltsas, Valerie Lewington, Silvia Minozzi, Michela Cinquini, Kjell Öberg, Wim J.G. Oyen, Dermot O’Toole, Marianne Pavel, Philippe Ruszniewski, Aldo Scarpa, Jonathan Strosberg, Anders Sundin, David Taïeb, Irene Virgolini, Damian Wild, Ken Herrmann, James C. Yao - European Journal of Cancer 2021 cited by 242

  9. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

    Authors: Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Enrique Grande, Jean‐Pierre Delord, Ronnie Shapira‐Frommer, Emily K. Bergsland, Manisha H. Shah, Marwan Fakih, Shunji Takahashi, Sarina A. Piha‐Paul, Bert H. O’Neil, Sajeve Thomas, Martijn P. Lolkema, Menghui Chen, Nageatte Ibrahim, Kevin Norwood, Julien Hadoux - Clinical Cancer Research 2020 cited by 221

  10. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

    Authors: Jonathan Strosberg, Þorvarður R. Hálfdánarson, Andrew M. Bellizzi, Jennifer A. Chan, Joseph S. Dillon, Anthony P. Heaney, Pamela L. Kunz, Thomas M. O’Dorisio, Riad Salem, Eva Segelov, James R. Howe, Rodney F. Pommier, Kari Brendtro, Mohammad Bashir, Simron Singh, Michael C. Soulen, Laura Tang, Jerome Zacks, James C. Yao, Emily K. Bergsland - Pancreas 2017 cited by 366

  11. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors

    Authors: Þorvarður R. Hálfdánarson, Jonathan Strosberg, Laura Tang, Andrew M. Bellizzi, Emily K. Bergsland, Thomas M. O’Dorisio, Daniel M. Halperin, Lauren Fishbein, Jennifer R. Eads, Thomas A. Hope, Simron Singh, Riad Salem, David C. Metz, Boris G. Naraev, Diane Reidy‐Lagunes, James R. Howe, Rodney F. Pommier, Yusuf Menda, Jennifer A. Chan - Pancreas 2020 cited by 196

  12. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

    Authors: Thomas A. Hope, Emily K. Bergsland, Murat Fani Bozkurt, Michael M. Graham, Anthony P. Heaney, Ken Herrmann, James R. Howe, Matthew H. Kulke, Pamela L. Kunz, Josh Mailman, Lawrence May, David C. Metz, Corina Millo, M. Sue O’Dorisio, Diane Reidy‐Lagunes, Michael C. Soulen, Jonathan Strosberg - Journal of Nuclear Medicine 2017 cited by 351

  13. A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort

    Authors: Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, Jonathan Strosberg, Jue Wang, Bhavana Konda, Jourdain Hayward, Christine M. McLeod, Helen X. Chen, Elad Sharon, Megan Othus, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock - Cancer 2021 cited by 112

  14. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer

    Authors: Richard D. Kim, Bence Kővári, María Carmen Riesco Martínez, Hao Xie, İbrahim Halil Şahin, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Masoumeh Ghayouri, Youngchul Kim, Dae Won Kim - European Journal of Cancer 2022 cited by 89

  15. Consensus on biomarkers for neuroendocrine tumour disease

    Authors: Kjell Öberg, Irvin M. Modlin, Wouter W. de Herder, Marianne Pavel, David S. Klimstra, Andrea Frilling, David C. Metz, Anthony P. Heaney, Dik J. Kwekkeboom, Jonathan Strosberg, T Meyer, Steven F. Moss, Kay Washington, Edward M. Wolin, Eric Liu, James R. Goldenring - The Lancet Oncology 2015 cited by 280

  16. NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

    Authors: Thomas A. Hope, Amanda Abbott, Karen Colucci, David Bushnell, Linda Gardner, W. S. Graham, Sheila Lindsay, David C. Metz, Daniel A. Pryma, Michael G. Stabin, Jonathan Strosberg - Journal of Nuclear Medicine 2019 cited by 172

  17. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

    Authors: Jaydira Del Rivero, Kimberly Perez, Erin B. Kennedy, Erik Mittra, Namrata Vijayvergia, Junaid Arshad, Sandip Basu, Aman Chauhan, Arvind Dasari, Andrew M. Bellizzi, Alexandra Gangi, Erin Grady, James R. Howe, Jana Ivanidze, Mark A. Lewis, Josh Mailman, Nitya Raj, Heloisa P. Soares, Michael C. Soulen, Sarah B. White, Jennifer A. Chan, Pamela L. Kunz, Simron Singh, Þorvarður R. Hálfdánarson, Jonathan Strosberg, Emily K. Bergsland - Journal of Clinical Oncology 2023 cited by 93

  18. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

    Authors: Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, Michael V. Knopp, Spencer C. Behr, Sydney Pulsipher, Fang‐Shu Ou, Amylou C. Dueck, Jared D. Acoba, Ardaman Shergill, Edward M. Wolin, Þorvarður R. Hálfdánarson, Bhavana Konda, Nikolaos A. Trikalinos, Bernard Tawfik, Nitya Raj, Shagufta Shaheen, Namrata Vijayvergia, Arvind Dasari, Jonathan Strosberg, Elise C. Kohn, Matthew H. Kulke, Eileen M. O’Reilly, Jeffrey A. Meyerhardt - New England Journal of Medicine 2024 cited by 136

  19. High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

    Authors: Abhishek Jha, David Taïeb, Jorge A. Carrasquillo, Daniel A. Pryma, Mayank Patel, Corina Millo, Wouter W. de Herder, Jaydira Del Rivero, Joakim Crona, Barry L. Shulkin, Irene Virgolini, Alice P. Chen, Bhagwant Rai Mittal, Sandip Basu, Joseph S. Dillon, Thomas A. Hope, Carina Marí Aparici, Andrei Iagaru, Rodney J. Hicks, Anca M. Avram, Jonathan Strosberg, A. Cahid Civelek, Frank I. Lin, Neeta Pandit‐Taskar, Karel Pacák - Clinical Cancer Research 2021 cited by 91

  20. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors

    Authors: Barbara Mandriani, Eleonora Pellè, Francesco Mannavola, Antonio J. Palazzo, Renè Massimiliano Marsano, Giuseppe Ingravallo, Gerardo Cazzato, María C. Ramello, Camillo Porta, Jonathan Strosberg, Daniel Abate‐Daga, Mauro Cives - Journal for ImmunoTherapy of Cancer 2022 cited by 34

  21. The Surgical Management of Small Bowel Neuroendocrine Tumors

    Authors: James R. Howe, Kenneth Cardona, Douglas L. Fraker, Electron Kebebew, Brian R. Untch, Yi-Zarn Wang, Calvin Law, Eric H. Liu, Michelle K. Kim, Yusuf Menda, Brian Morse, Emily K. Bergsland, Jonathan Strosberg, Eric K. Nakakura, Rodney F. Pommier - Pancreas 2017 cited by 363

  22. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines

    Authors: Simron Singh, Emily K. Bergsland, Cynthia Card, Thomas A. Hope, Pamela L. Kunz, David Laidley, Ben Lawrence, Simone Leyden, David C. Metz, Michael Michael, Lucy Modahl, Sten Myrehaug, Sukhmani K. Padda, Rodney F. Pommier, Robert A. Ramirez, Michael C. Soulen, Jonathan Strosberg, Arthur Sung, Alia Thawer, Benjamin Wei, Bin Xu, Eva Segelov - Journal of Thoracic Oncology 2020 cited by 116

  23. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood

    Authors: K. Öberg, Andrea Califano, Jonathan Strosberg, Shuangge Ma, Ulrich‐Frank Pape, Lisa Bodei, Gregory Kaltsas, Christos Toumpanakis, James R. Goldenring, Andrea Frilling, S. Paulson - Annals of Oncology 2020 cited by 115

  24. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials

    Authors: Namrata Vijayvergia, Arvind Dasari, Mengying Deng, Samuel Litwin, Taymeyah Al‐Toubah, R. Katherine Alpaugh, Efrat Dotan, Michael J. Hall, Nicole Ross, Melissa M. Runyen, Crystal S. Denlinger, Daniel M. Halperin, Steven J. Cohen, Paul F. Engstrom, Jonathan Strosberg - British Journal of Cancer 2020 cited by 111